Pascale Augé is a recognized expert in life sciences and health innovation, with nearly 30 years of experience in research valorization, entrepreneurship, and strategic development. Since 2014, she has served as Chair of the Executive Board of Inserm Transfert, where she drives a culture of excellence to accelerate the transfer of innovations from public research to industry and patients.

Pascale Augé has held strategic positions at the heart of the biotechnology and health startup ecosystem. Before joining Inserm Transfert, she led the Technology Transfer and Entrepreneurship Department at the Institut Pasteur in Paris from 2011 to 2014. Her expertise also extends to business development and preclinical/early clinical development (Neurotech, Entomed, AB Science), as well as operational strategy consulting, particularly at EY, where she managed life sciences and health technology activities for France.

From 2008 to 2011, Pascale chaired the evaluation committee for the French National Research Agency’s (ANR) program on “Emerging products, technologies, or services with high valorization potential.” Since 2015, she has served on the Board of Directors of LFB SA, a leading French pharmaceutical company, and has been actively involved in the Supervisory Board of Inserm Transfert Initiative (seed fund) and EMBLEM Technology Transfer GmbH, the technology transfer subsidiary of EMBL, since 2022. Since 2019, she has been an expert for the EIC Accelerator and Transition programs.

In 2022, Pascale Augé facilitated Inserm Transfert’s entry into the AFB Fund II managed by AdBio Partners, strengthening support for innovative health startups. In 2024, she co-founded AndzonBio® with Alain Huriez, a “pipeline company builder” platform designed to accelerate the development of promising academic projects in life sciences and digital health. Two companies have already emerged from this initiative: AndzonBio1 (focused on cardiovascular, metabolic, and renal diseases) and AndzonBio2 (focused on neuro-inflammatory diseases), where she serves as a strategic board member.

Pascale Augé holds a PhD in molecular pharmacochemistry, experimental pharmacology, and metabolism (Université Paris Cité) and is a chemical engineer (École de Chimie de Strasbourg).